Article R5121-152
…": a noxious and unintended response to a medicinal product or to a product mentioned in Article R. 5121-150 ; 2° "Serious adverse reaction": an adverse reaction which is lethal or life-threatening, o…
20+ full codes, 2,400+ articles translated and updated. Case law linked to every article. Read the actual text before you ask a lawyer about it — free, no login required.
20+
french codes
Fully translated
2,400+
articles in English
Updated regularly
480+
court rulings linked
Per article
Free
full access
No login required
Showing 10551–10560 of 36632 articles for “Art. al. 5”
…": a noxious and unintended response to a medicinal product or to a product mentioned in Article R. 5121-150 ; 2° "Serious adverse reaction": an adverse reaction which is lethal or life-threatening, o…
…harmacist may present for direct access to the public under the conditions set out in article R. 4235-55. It is published on the Agency's website. At the request of the marketing authorisation holder…
The data referred to in II and III of Article R. 5121-201-5 and a copy of the administration record referred to in Article R. 5121-201-6 shall be kept by the establishments referred to in Article R. 5…
I.-This article applies to the post-authorisation studies referred to in article R. 5121-178 which are carried out by the holder of the authorisation referred to in article L. 5121-8 in order to compl…
The company or organisation exploiting a medicinal product or a product referred to in Article R. 5121-150 may not communicate information relating to pharmacovigilance to the general public about thi…
Without prejudice to the provisions of Article L. 5122-7, advertising of a medicinal product to the general public may not include any element which : 1° Makes medical consultation or surgical interve…
The authorisation may be subject to special conditions requiring the beneficiary of the authorisation to implement a plan for monitoring the efficacy and safety of the medicinal product, including the…
…of interruption or cessation of activity of a pharmaceutical establishment mentioned in article L. 5124-1 or article L. 5124-9-1 manufacturing advanced therapy medicinal products prepared on an ad ho…
…a blood-derived medicinal product directly to a patient, the information referred to in article R. 5121-187 is transcribed onto a special register marked and initialled by the mayor or police commiss…
The holder of the authorisation provided for in Article L. 4211-6 is required to report the following to the Director General of the Agence nationale de sécurité du médicament et des produits de santé…
Avocate au Barreau de Paris
Toque #C2396
15+ Years In French Corporate Practice
English · French · Russian
Ready When You Are
A 20–30 minute call, in English, to scope the engagement. No obligation, no preliminary fee. You will leave the call with a clear view of what the work will cover and what it will cost.
20+ full codes and 2,400+ articles in English, with the key court rulings linked to every article — free to read.
Read MoreA lawyer-reviewed report explaining how the relevant articles apply to your situation, with case-law analysis and next steps.
Read MoreScope your matter with a Paris-Bar avocate — incorporation, contracts, disputes — handled bilingually, end to end.
Read More